Natalizumab (Tysabri▼): risk of progressive multifocal leukoencephalopathy increases after 2 years of therapy

Source:
GOV UK
Publisher:
Medicines and Healthcare products Regulatory Agency
Publication date:
11 December 2014

Abstract

The risk of developing progressive multifocal leukoencephalopathy (PML) with natalizumab increases after 2 years of therapy.